the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection

SARS-CoV2 Infection Clinical Trial

Official title:

the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04893694
• Other study ID #: Oral SARS 2
• Status: Completed
• Start date: May 20, 2021
• Est. completion date: July 15, 2021

Study information

• Verified date: August 2021
• Source: Fayoum University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection

Description:

The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands and soft tissues . Moreover, oral mucosa can be affected by secondary pathological process of a bacterial or fungal nature due to viral immunosuppression. The oral cavity could be considered a "biological barometer" of both viral infection and viral immunosuppression advancement .

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection .

Although many authors reported the presence of oral lesion associated with SARS-CoV2 infection, the prevalence of the oral manifestation and the range of oral manifestation are still unknown. Further studies are necessary to better understanding of the symptoms of the SARS-CoV2 virus in order to faster detection. A multidisciplinary team following the patients could be the key in treatment of the infection and faster recovery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 385
• Est. completion date: July 15, 2021
• Est. primary completion date: June 20, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• A diagnosis of SARS-CoV2 with PCR.

• Age range from 18-60 years old

• Hospital admission not more than 10 days

Exclusion Criteria:

• Pregnancy or contraceptive pills

• Lactation

• Any auto-immune disease that could affect the oral mucosa

• On any neoplastic therapy.

• Uncontrolled diabetes.

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Oral Manifestations
• SARS-CoV2 Infection

Locations

Country	Name	City	State
Egypt	Faculty of Dentistry	Fayoum

Sponsors (2)

Lead Sponsor	Collaborator
Fayoum University	Ministry of Health and Population, Egypt

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Dziedzic A, Wojtyczka R. The impact of coronavirus infectious disease 19 (COVID-19) on oral health. Oral Dis. 2021 Apr;27 Suppl 3:703-706. doi: 10.1111/odi.13359. Epub 2020 May 6. — View Citation

Riad A, Klugar M, Krsek M. COVID-19-Related Oral Manifestations: Early Disease Features? Oral Dis. 2020 Jun 30. doi: 10.1111/odi.13516. [Epub ahead of print] — View Citation

Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oral Manifestation	presence or absence of Oral Manifestation in SARS-CO2	one week